Rawlins image

Sir Michael Rawlins appointed chair of MHRA

pharmafile | November 4, 2014 | News story | Manufacturing and Production, Medical Communications, Sales and Marketing MHRA, NHS, NICE, gordon duff, michael rawlins 

The Medicines and Healthcare Products Regulatory Agency (MHRA) has confirmed that former NICE head Sir Michael Rawlins is to serve as its new chair.

Taking up the post from December, his appointment is set to last three years and he takes over from Sir Gordon Duff who announced his intention to step down earlier this year – following his election as Principal of St Hilda’s College, Oxford.

Sir Michael was until recently chair of the National Institute of Health & Clinical Excellence until 2013, and he is also currently chairman of Biobank.

Sir Michael says: “It will be a tremendous honour to take up the agency’s chair, whose vital work as the UK’s regulator of medicines and medical devices is underpinned by first-class science and research carried out at each of the agency’s centres; the Clinical Practice Research Datalink (CPRD), the National Institute for Biological Standards and Control (NIBSC) and MHRA.

Sir Gordon adds: “I am delighted at the appointment of Sir Michael Rawlins as agency chair. In Sir Michael, the agency is getting an experienced, highly respected and influential public health expert who will prove a real asset in meeting the challenges to come.

“I am proud of what the agency has achieved in the last two years, not least in the ongoing day-to-day regulation of medicines and medical products but also through the leading role the agency plays, both at home and on the global stage. I wish Sir Michael and all agency staff every success as they continue their invaluable work.”

Chief medical officer, Dame Sally Davies concludes: “I am delighted at Sir Michael Rawlins’ appointment as agency chair. He will bring a wealth of experience to the board and will play a key role in the leadership of our national regulator who will continue to focus on excellence and innovation.

Brett Wells

Related Content

NICE recommends migraine treatment for NHS use

The National Institute for Health and Care Excellence (NICE) has shared draft guidance recommending AbbVie’s …

robina-weermeijer-ihfopazzjhm-unsplash_5

MHRA approves Takeda’s Hyqvia for chronic inflammatory demyelinating polyneuropathy treatment

Takeda has announced that the Medicines and Healthcare Products Regulatory Agency (MHRA) has granted marketing …

GSK’s Jemperli recommended by NICE for endometrial cancer treatment

GSK has announced that the National Institute for Health and Care Excellence (NICE) has recommended …

Latest content